Skip to main content

System maintenance notice:

Site Search and Location Search will be unavailable from 1am-6am Eastern on Sunday, December 3. Thank you for your patience.

Hide
Quest Diagnostics Home

Assessing therapeutics

Assessing therapeutics can help inform the path forward

Tumor necrosis factor (TNF) blockers, such as adalimumab (Humira®), infliximab (Remicade®), and the infliximab biosimilar infliximab-dyyb (Inflectra®), are used to treat inflammatory bowel disease (IBD; Crohn disease, ulcerative colitis) and rheumatic diseases (eg, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis).1-3

TNF blockers have had a major impact on the course of treatment for these conditions, but response rates vary by indication and other factors (eg, dose, smoker vs nonsmoker, etc.). While some patients respond to treatment, many others are refractory to treatment, showing either nonresponse during induction (primary failure) or response during induction followed by loss of efficacy (secondary failure).

When treatment fails, a physician may need to consider other treatment options, such as adjusting dose or dosing intervals, switching to a different TNF blocker, or switching to a non–TNF blocker. Measuring TNF blocker drug levels can help differentiate pharmacodynamic from possible pharmacokinetic conditions associated with treatment failure. 

Irritable bowel disease

The American Gastroenterology Association (AGA) suggests a testing-based strategy when control of active IBD is suboptimal.4

Individuals suitable for testing:

  • Individuals with IBD who have recently started treatment with adalimumab, infliximab, or the biosimilar infliximab (baseline testing)
  • Individuals who experience treatment failure with any of these drugs
Adalimumab Level and
Anti-drug Antibody for IBD
Infliximab Level and
Anti-drug Antibody for IBD

Rheumatic disease

Individuals suitable for testing:

  • Individuals with a rheumatic disease who have experienced failure of treatment with adalimumab, infliximab, or the infliximab biosimilar infliximab 
Adalimumab Drug Level and
Anti-drug Antibody for Rheumatic Diseases
Infliximab Level and Anti-drug
Antibody for Rheumatic Diseases

 

References

  1. HUMIRA® (adalimumab). Prescribing information. AbbVie Inc; 2020. Accessed May 13, 2020. https://www.rxabbvie.com/pdf/humira.pdf
  2. REMICADE® (infliximab). Prescribing information. Janssen Biotech Inc; 2020. Accessed June 29, 2020. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/REMICADE-pi.pdf
  3. INFLECTRA® (infliximab-dyyb). Prescribing information. Pfizer Inc; 2019. Accessed May 13, 2020. http://labeling.pfizer.com/ShowLabeling.aspx?id=9271
  4. Crohn’s & Colitis Foundation of America. The facts about inflammatory bowel diseases. November 2014. Accessed March 8, 2019. Available at http://www.crohnscolitisfoundation.org/assets/pdfs/updatedibdfactbook.pdf

Questions?

Your Quest account representative is ready to discuss how we can meet your ANA testing needs. 

Contact us

Autoimmune diseases

Resources

Clinical Focus: Inflammatory bowel disease

Clinical Focus: TNF blockers for IBD

Clinical Focus: TNF blockers for rheumatic diseases

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.